Logo

RVTY

Revvity, Inc.

RVTY

Revvity, Inc. • NYSE
$104.41 ▼ -0.24% (-0.25)
Market Cap $12.39 B
52w High $128.29
52w Low $81.36
Dividend Yield 0.28%
P/E 53.82
Volume 399.77K
Outstanding Shares 118.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $698.949M ▼ $292.708M ▼ $46.652M ▼ 6.675% ▼ $0.4 ▼ $180.517M ▼
Q2-2025 $720.284M ▲ $301.796M ▲ $55.222M ▲ 7.667% ▲ $0.47 ▲ $194.365M ▲
Q1-2025 $664.762M ▼ $239.275M ▲ $41.437M ▼ 6.233% ▼ $0.345 ▼ $172.768M ▼
Q4-2024 $729.372M ▲ $227.402M ▼ $95.036M ▲ 13.03% ▼ $0.78 ▲ $222.372M ▼
Q3-2024 $684.049M $282.217M $93.965M 13.737% $0.765 $232.41M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $931.386M ▼ $12.139B ▼ $4.763B ▼ $7.376B ▼
Q2-2025 $991.849M ▼ $12.363B ▲ $4.807B ▲ $7.556B ▼
Q1-2025 $1.138B ▼ $12.361B ▼ $4.724B ▼ $7.637B ▼
Q4-2024 $1.163B ▼ $12.392B ▼ $4.726B ▼ $7.667B ▼
Q3-2024 $1.23B $12.77B $4.848B $7.922B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $46.652M ▼ $138.581M ▲ $18.97M ▲ $-215.074M ▲ $-60.415M ▲ $120.08M ▲
Q2-2025 $55.222M ▲ $134.318M ▲ $-9.493M ▼ $-302.475M ▼ $-145.697M ▼ $115.45M ▲
Q1-2025 $41.669M ▼ $128.155M ▼ $-6.378M ▲ $-163.664M ▲ $-25.765M ▲ $112.173M ▼
Q4-2024 $88.383M ▼ $174.23M ▲ $-17.329M ▼ $-192.99M ▲ $-66.356M ▼ $149.776M ▲
Q3-2024 $93.386M $147.885M $690.181M $-873.737M $-18.62M $125.566M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Diagnostics
Diagnostics
 $1.12Bn ▲$320.00M ▼$350.00M ▲$360.00M ▲
Life Sciences
Life Sciences
 $950.00M ▲$340.00M ▼$370.00M ▲$340.00M ▼

Five-Year Company Overview

Income Statement

Income Statement Revvity’s income statement shows a company in transition. Sales have stepped down from earlier peaks as it exited some businesses and moved past the pandemic testing boom, but they now look more stable rather than still falling. Profitability has weakened compared with a few years ago, with operating profit and net income meaningfully lower than past highs and one recent year slipping into a small loss. The most recent year, however, shows a return to solid profitability and a slight improvement in operating performance, suggesting the business is beginning to adjust to its new shape, even if earnings are not yet back to prior levels.

Balance Sheet

Balance Sheet The balance sheet reflects a moderate but manageable risk profile. Total assets and shareholder equity have grown significantly compared with several years ago, mainly due to acquisitions and portfolio reshaping, and have stayed fairly steady more recently. Debt is sizeable and increased during the expansion period, but it has started to come down, which is a positive sign for balance sheet discipline. Cash on hand is not especially large but has improved versus earlier years, indicating a somewhat better liquidity cushion, though the company still needs consistent cash generation to comfortably support its obligations and ongoing investments.

Cash Flow

Cash Flow Revvity remains a cash-generating business, but its cash flows have been bumpy. Operating and free cash flow were strong in the earlier part of the period, dipped to very low levels during the portfolio transition, and then recovered meaningfully in the most recent year, albeit not yet back to their former strength. Capital spending is modest and steady, so most of the movement comes from changes in underlying profitability and working capital. Overall, the pattern suggests a company that can produce healthy cash over time, but with execution and integration swings that can tighten cash in certain years.

Competitive Edge

Competitive Edge Competitively, Revvity sits in attractive niches of life sciences and diagnostics, with a broad toolkit spanning instruments, reagents, services, and software. Its ability to offer integrated end-to-end workflows—from research through diagnosis—is a clear strength and can be convenient for customers. The company also benefits from established relationships in pharma, biotech, and clinical labs, plus a significant role in areas like newborn screening. At the same time, external assessments indicate that its long-term competitive “moat” may be less robust than once thought, with customers able to switch to rivals and intense competition across many of its markets. The portfolio reset and rebranding have sharpened its focus but also raised the bar to prove that this narrower, more specialized business can consistently deliver strong returns.

Innovation and R&D

Innovation and R&D Innovation is a central pillar for Revvity. The company is leaning heavily into data-centric and software-enabled solutions, particularly through its Signals platform, which aims to unite scientific data, improve collaboration, and embed analytics into research and clinical workflows. It is also investing in advanced areas such as multi-omics, biomarker discovery, AI-powered imaging analysis, and base-editing technologies, often pairing instruments and reagents with sophisticated software. Acquisitions like ACD/Labs and the introduction of clinical data platforms signal a push to become deeply embedded in customers’ digital and analytical infrastructure. In diagnostics, ongoing work in newborn sequencing, reproductive health, and specialized analyzers points to a steady stream of product innovation. The key question is less about the volume of innovation and more about how effectively Revvity turns these advances into sticky, high-margin, recurring revenue streams.

Summary

Revvity is a reshaped life sciences and diagnostics company moving from a broader industrial footprint to a more focused, higher-growth profile. Financially, revenue and profit have reset to lower levels after divestitures and pandemic-related tailwinds faded, but recent results show signs of stabilization and gradual improvement. The balance sheet carries meaningful debt but appears on a de-risking path, supported by improving cash generation after a soft patch. Competitively, Revvity’s strength lies in integrated workflows, deep scientific know-how, and growing software and data offerings, though external views suggest its customer switching costs and overall moat are not unassailable. Its innovation strategy—especially in software, AI, and genomics-driven diagnostics—positions it well for long-term industry trends, but execution on integration, margin rebuilding, and consistent cash flow will be critical in determining how much of that potential translates into durable financial performance.

NEWS

November 10, 2025 · 8:00 AM UTC

Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy

Read more

November 10, 2025 · 7:45 AM UTC

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

Read more

October 28, 2025 · 8:00 AM UTC

Revvity to Present at Upcoming Investor Conferences

Read more

October 27, 2025 · 6:00 AM UTC

Revvity Announces Financial Results for the Third Quarter of 2025

Read more

October 23, 2025 · 4:05 PM UTC

Revvity Board Declares Quarterly Dividend

Read more